Pieris Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview

Palvella Therapeutics

31/07/2023 14:01

* Pieris Pharmaceuticals Inc  PIRS.OQ   PIRS.O  is expected
to show a rise in quarterly revenue when it reports  results on
August 2 (estimated). 
    * The Boston Massachusetts-based  company is expected to
report  a
8.7% increase in revenue to $4.019 million from $3.7 million a
year ago, according to the estimate from one analyst, based on
Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Pieris
Pharmaceuticals
Inc is for a loss of 16 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Pieris
Pharmaceuticals Inc is $7​, above​ its last closing price
of $0.22. ​​​

This summary was machine generated July 31 at 13:01 GMT.  All
figures in US dollars  unless otherwise stated